–Eyes on the FDA approval of fruquintinib in Nov
Positive profit alert for FY22; eyeing for a good FY23E
China Technology–Global fabless/IDM 2Q23 wrap: expect continued inventory correction for non-AI players; All eyes on NVDA 3Q23E guidance
1H23E earnings preview: All eyes on the Galaxy
2024叶黄素护眼选购白皮书—EYE护双眼,素速开始
Eyeing on the pace of fundamental recovery post sentiment rebound
All eyes on 4Q24E for the room of re-rating
Eyes on monetization potential and margin improvement trajectory
–Eye on upcoming launch of Twist of the Fate
An Eye on Methane: International Methane Emissions Observatory 2023 Report